U.K. agency suggests restriction on use of drug-eluting stents

09/24/2008 | FDAnews

The use of drug-eluting stents should be limited to coronary-artery disease patients who would likely require future interventions if they received a conventional bare-metal stent instead, according to a final guidance from the U.K.'s National Institute for Health and Clinical Excellence. NICE's final guidance offers data on specific drug-coated stents and their individual prices.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT